Question explored with the scientific record
Conversation so far
- 1 Are travel vaccines effective?
- 2 Which travel vaccine has best evidence for effectiveness?
Answered on this page ↓
Which travel vaccine has best evidence for effectiveness?
The retrieved evidence does not directly compare travel vaccines head-to-head for effectiveness, so the answer comes from what the records do show about individual vaccines.
The strongest effectiveness numbers in these records are for yellow fever vaccine in adults, where a single dose produces protective antibody levels that last for decades, and for rabies pre-exposure vaccine, which reliably produces protective antibody levels in nearly everyone who completes the series [2, 6]. The yellow fever vaccine has decades of use and a known safety profile, though serious adverse events are higher in people over 70 (about 10 per 100,000 doses) than in those 60-69 (about 6.5 per 100,000) [2].
Typhoid vaccines have weaker and more variable evidence. The injectable Vi polysaccharide vaccine showed 74% efficacy in one field trial in Nepal, but the oral Ty21a vaccine dropped to 23% efficacy in travelers to India [4]. Neither vaccine protects against paratyphoid fever, which accounts for a growing share of enteric fever in travelers [5]. Hepatitis A vaccine is effective at preventing disease, but the evidence here is about public health strategy, not traveler-specific efficacy numbers [1].
| Vaccine | Best reported effectiveness | Key limitation |
|---|---|---|
| Yellow fever (adults) | Single dose, protective for decades [2] | Higher serious AE rate over age 70 |
| Rabies (pre-exposure) | >97% seroconversion [6] | Requires 3 doses; expensive |
| Typhoid Vi (injectable) | 74% in Nepal field trial [4] | No protection against paratyphoid |
| Typhoid Ty21a (oral) | 23% in travelers to India [4] | Poor real-world compliance [3] |
| Hepatitis A | Effective, no traveler-specific rate here [1] | Evidence is about population strategy |
The dengue vaccine TAK-003 showed 81% efficacy against all serotypes in people who had prior dengue infection, but benefit is uncertain in those without prior infection, and no data exists for travelers over 60 [2]. The malaria vaccine ProC6C showed 54% efficacy in a small phase 2 trial in Malian adults, but this is not yet a standard travel vaccine [7].
My call: yellow fever and rabies pre-exposure vaccines have the strongest evidence for effectiveness in travelers, but the evidence base is thin for most travel vaccines when judged by hard clinical outcomes in travelers specifically. Confidence: moderate for yellow fever and rabies; low for typhoid and dengue in travelers.
Sources used 7
-
Who should receive hepatitis A vaccine?
Hepatitis A vaccination should be targeted according to local epidemiological and socioeconomic conditions; universal immunization is effective but impractical in many countries, and selective immunization of high-risk groups has not yet achieved desired impact.
DOI: 10.1046/j.1365-2893.2003.00422.x -
Travel vaccination in senior travelers: current evidence, challenges, and prevention
Vaccination in senior travelers should be individualized and exposure-based, prioritizing routine vaccines while weighing yellow fever and emerging dengue/chikungunya vaccines against age-specific risks; age-specific evidence remains limited.
DOI: 10.1186/s40794-026-00315-1 -
Compliance with oral typhoid vaccine Ty21a in travellers
This study assesses the compliance of travellers with the oral typhoid vaccine Ty21a, finding that 79.1% of participants adhered to the vaccination schedule despite its complexity.
DOI: 10.1016/s1576-9887(03)70312-4 -
Typhoid and paratyphoid fever in travellers
This study reviews the epidemiology, clinical features, treatment, and vaccine efficacy of enteric fever, particularly focusing on the impact of travel to endemic regions and the rising antibiotic resistance of Salmonella typhi and Salmonella paratyphi.
DOI: 10.1016/s1473-3099(05)70239-5 -
ENTERIC FEVER IN TRAVELERS: AN UPDATED INSIGHT
A comprehensive narrative review updating the epidemiology, clinical features, diagnostics, prevention, treatment, and vaccine considerations of enteric fever among travelers, highlighting rising antimicrobial resistance, the predominance of Salmonella Typhi and Paratyphi, and t…
DOI: 10.22159/ajpcr.2016.v9s3.14543 -
Evaluation of rabies immunogenicity and tolerability following a purified chick embryo cell rabies vaccine administered concomitantly with a Japanese encephalitis vaccine
Accelerated one-week concomitant vaccination with a rabies vaccine and a Japanese encephalitis vaccine is non-inferior in immunogenicity and has a comparable safety profile to standard regimens in healthy adults, offering a convenient option for short-notice travelers.
DOI: 10.1016/j.tmaid.2015.05.008 -
Industry Insights: Maternal vaccine safety, controversial policy changes, and the surprising link between tattoo ink and vaccine response
This vaccine news roundup reports recent findings including tattoo ink altering vaccine responses, RSV maternal vaccine safety, COVID-19 vaccination in pregnancy, inferiority of fractional yellow fever dose in infants, and malaria vaccine efficacy.
DOI: 10.18609/vac.2026.001